124 related articles for article (PubMed ID: 32060315)
1. Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation.
Hermosilla J; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Bones J; Navas N
Sci Rep; 2020 Feb; 10(1):2675. PubMed ID: 32060315
[TBL] [Abstract][Full Text] [Related]
2. Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies.
Hermosilla J; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Navas N
J Pharm Biomed Anal; 2021 Sep; 203():114209. PubMed ID: 34153938
[TBL] [Abstract][Full Text] [Related]
3. Intact charge variant analysis of ziv-aflibercept by cationic exchange liquid chromatography as a proof of concept: Comparison between volatile and non-volatile salts in the mobile phase.
Pérez-Robles R; Cuadros-Rodríguez L; Salmerón-García A; Cabeza-Barrera J; Navas N
J Pharm Biomed Anal; 2020 Jun; 185():113233. PubMed ID: 32169790
[TBL] [Abstract][Full Text] [Related]
4. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
5. Study of stability and biophysical characterization of ranibizumab and aflibercept.
Moreno MR; Tabitha TS; Nirmal J; Radhakrishnan K; Yee CH; Lim S; Venkatraman S; Agrawal R
Eur J Pharm Biopharm; 2016 Nov; 108():156-167. PubMed ID: 27615995
[TBL] [Abstract][Full Text] [Related]
6. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
7. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
[TBL] [Abstract][Full Text] [Related]
8. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
9. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration.
de Oliveira Dias JR; Xavier CO; Maia A; de Moraes NS; Meyer C; Farah ME; Rodrigues EB
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):91-4. PubMed ID: 25559518
[TBL] [Abstract][Full Text] [Related]
11. Ziv-aflibercept (Zaltrap) for metastatic colorectal cancer.
Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836346
[No Abstract] [Full Text] [Related]
12. Fusion Proteins: Aflibercept (VEGF Trap-Eye).
Sarwar S; Bakbak B; Sadiq MA; Sepah YJ; Shah SM; Ibrahim M; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():282-94. PubMed ID: 26501481
[TBL] [Abstract][Full Text] [Related]
13. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
[TBL] [Abstract][Full Text] [Related]
14. Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.
Ashraf M; Souka AA; El Kayal H; El Manhaly M; Abdallah MH
Acta Ophthalmol; 2016 Nov; 94(7):e669. PubMed ID: 27227354
[No Abstract] [Full Text] [Related]
15. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT.
Yogi R; Stewart M; Chhablani J
Retin Cases Brief Rep; 2017 Spring; 11(2):111-113. PubMed ID: 27078613
[TBL] [Abstract][Full Text] [Related]
16. Sustained Anti-Vascular Endothelial Growth Factor Activity of Aflibercept (Eylea) After Storage in Polycarbonate Syringes Used for Intravitreal Injection: A Pathway to Safety and Efficiency.
Han DP; Skumatz C; Besharse JC; Kassem IS
J Ocul Pharmacol Ther; 2019 Jun; 35(5):278-282. PubMed ID: 30916605
[No Abstract] [Full Text] [Related]
17. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT.
Chhablani J; Narayanan R; Mathai A; Yogi R; Stewart M
Retina; 2016 Jun; 36(6):1126-31. PubMed ID: 26655620
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of ziv-aflibercept in retinal diseases.
Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J
Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.
Ivanova JI; Saverno KR; Sung J; Duh MS; Zhao C; Cai S; Vekeman F; Peevyhouse A; Dhawan R; Fuchs CS
Med Oncol; 2017 Nov; 34(12):193. PubMed ID: 29103187
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept efficacy in refractory choroidal neovascularization.
Brănişteanu DC; Bîlhă A; Moraru A
Rom J Ophthalmol; 2016; 60(2):96-102. PubMed ID: 29450330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
